Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Abstract

Serotonergic involvement in haloperidol-induced catalepsy.

B S Neal-Beliveau, J N Joyce and I Lucki
Journal of Pharmacology and Experimental Therapeutics April 1993, 265 (1) 207-217;
B S Neal-Beliveau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J N Joyce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Lucki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The ability of serotonin (5-HT)-selective compounds to reverse catalepsy due to blockade of dopamine (DA) receptors was examined in rats treated with the antipsychotic haloperidol (HAL). The 5-HT-releasing drug fenfluramine significantly reversed HAL-induced catalepsy. The 5-HT1A receptor agonists 8-hydroxy-2-(di-n-propylamino)tetralin and buspirone potently and dose-dependently reversed HAL-induced catalepsy. The effect of 8-hydroxy-2-(di-n-propylamino)tetralin was blocked by pretreatment with the 5-HT1A/1B receptor antagonist pindolol, but not the 5-HT2 receptor antagonist ketanserin. The 5-HT1C/2 receptor agonist 2,5-dimethoxy-4-bromoamphetamine also completely reversed HAL-induced catalepsy, an effect blocked by ketanserin, but not pindolol. Neither antagonist alone had any effect. The 5-HT1B/1C receptor agonist trifluoromethylphenylpiperazine only partially reversed HAL-induced catalepsy, and the effect was not dose dependent. The 5-HT1C/2 receptor antagonist mianserin reversed HAL-induced catalepsy on its own; therefore, its ability to block the effect of trifluoromethylphenylpiperazine could not be tested. The nature of the disruption of HAL-induced catalepsy was examined by measuring the ability of increasing doses of HAL to surmount the effects of the serotonergic agonists. The mixed DA-D1/D2 receptor agonist apomorphine shifted the dose-effect curve for HAL to the right in a parallel manner, indicative of a competitive interaction between HAL and apomorphine at the D2 receptor. In contrast, the 5-HT receptor agonists flattened the dose-effect curve for HAL, suggestive of noncompetitive interactions. These data suggest that the 5-HT receptor agonists are not reversing HAL-induced catalepsy by indirectly increasing DA release. Rather, the agonists reverse HAL-induced catalepsy through interactions at their specific 5-HT receptor subtypes. Thus, the 5-HT receptor agonists may provide novel approaches for the development of drugs which can reverse or prevent the extrapyramidal side effects associated with antipsychotic treatment.

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 265, Issue 1
1 Apr 1993
  • Table of Contents
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Serotonergic involvement in haloperidol-induced catalepsy.
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Serotonergic involvement in haloperidol-induced catalepsy.

B S Neal-Beliveau, J N Joyce and I Lucki
Journal of Pharmacology and Experimental Therapeutics April 1, 1993, 265 (1) 207-217;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Serotonergic involvement in haloperidol-induced catalepsy.

B S Neal-Beliveau, J N Joyce and I Lucki
Journal of Pharmacology and Experimental Therapeutics April 1, 1993, 265 (1) 207-217;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics